Cargando…
Activity-Based Protein Profiling Delivers Selective Drug Candidate ABX-1431, a Monoacylglycerol Lipase Inhibitor, To Control Lipid Metabolism in Neurological Disorders
Monoacylglycerol lipase (MGLL or MAGL) is a critical point of regulation of both endocannabinoid and eicosanoid signaling pathways in the brain, thereby providing novel therapeutic opportunities for neurological and neurodegenerative diseases. In this issue Cisar et al. disclose the discovery, optim...
Autores principales: | Jiang, Ming, van der Stelt, Mario |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2018
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6204598/ https://www.ncbi.nlm.nih.gov/pubmed/30354159 http://dx.doi.org/10.1021/acs.jmedchem.8b01405 |
Ejemplares similares
-
ABX-1431 inhibits the development of endometrial adenocarcinoma and reverses progesterone resistance by targeting MGLL
por: Ma, Xiaohong, et al.
Publicado: (2022) -
Monoacylglycerol lipase inhibitors: modulators for lipid metabolism in cancer malignancy, neurological and metabolic disorders
por: Deng, Hui, et al.
Publicado: (2020) -
Targeting Monoacylglycerol Lipase in Pursuit of Therapies for Neurological and Neurodegenerative Diseases
por: Zanfirescu, Anca, et al.
Publicado: (2021) -
Monoacylglycerol lipase reprograms lipid precursors signaling in liver disease
por: Tardelli, Matteo
Publicado: (2020) -
Monoacylglycerol Lipase Regulates Fever Response
por: Sanchez-Alavez, Manuel, et al.
Publicado: (2015)